UNSPSC 51124403: Digitoxin

This classification denotes an enzyme inhibitor and cardiotonic agent with the molecular formula C41H64O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) E90NZP2L9U, chemically known as purodigin, crystalline but more generally known as digitoxin, which bears US NIH Compound Identifier 3061. European Medicines Agency schedules Digitoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07133MIG. The term DIGITOXIN is an International Non-Proprietary Name.

UNSPSC 51124403 Digitoxin is a Commodity code covering pharmaceutical ingredients and finished medications procured by state and local health and emergency-services agencies. Recent state and local solicitations under this code show demand for advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products supplied through established pharmaceutical distribution channels. The City of Tampa's fire-rescue system and state health agencies are representative buyers, with procurement vehicles including direct sealed-bid contracts and cooperative purchasing arrangements that aggregate demand across multiple state and local jurisdictions. Vendors supply products through authorized pharmaceutical wholesalers, must maintain cGMP and Drug Supply Chain Security Act compliance, and meet strict expiration-date and shelf-life requirements—typically nine months or more from acceptance through delivery, with six-month minimum shelf life for contract agreements. Pricing is firm, freight-on-board, inclusive of taxes, and vendors warrant defect-free materials for a minimum of 365 days.

Activity centers in Florida and the Upper Midwest, with standout buyers including the City of Tampa (Hillsborough County), the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission. The City of Tampa issued a sealed-bid solicitation (26P00188) with a due date of April 8, 2026, for four specific advanced life support medication line items valued at approximately $40,000, requiring delivery within ten calendar days and offering a 5 percent SLBE bid discount. MMCAP issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products effective July 1, 2026, across Minnesota, Oregon, and participating jurisdictions, with evaluation weighted 75 percent on price competitiveness. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling future formal procurement interest. Vendors must submit detailed product information including NDC codes, maintain comprehensive insurance including $5,000,000 commercial general liability, and comply with FDA requirements and OSHA Hazard Communication Standards.